Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2017 October;69(5) > Minerva Ginecologica 2017 October;69(5):425-30

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Ginecologica 2017 October;69(5):425-30

DOI: 10.23736/S0026-4784.17.04053-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Efficacy of carboxymethyl beta-glucan in cervical intraepithelial neoplasia: a retrospective, case-control study

Patrizia STENTELLA 1, Alberto BIAMONTI 2, Carlo CARRARO 1, Paolo INGHIRAMI 3, Pasquale MANCINO 1, Daniela PIETRANGELI 1, Sergio VOTANO 4, Paola LAZZARI 1, Caterina DE MEDICI 1

1 Department of Obstetrics, Gynecology and Urology, Sapienza University, Rome, Italy; 2 Department of Obstetrics and Gynecology, Cristo Re Hospital, Rome, Italy; 3 Department of Obstetrics and Gynecology, Sant’Eugenio Hospital, Rome, Italy; 4 Department of Obstetrics and Gynecology, San Carlo di Nancy Hospital, Rome, Italy


PDF


BACKGROUND: Persistent human papillomavirus (HPV) infection constitutes the principal risk factor for the development of cervical intraepithelial neoplasia (CIN) and cervical cancer. For this reason, new drugs have been studied to support the host immune system against the HPV infection. The aim of this retrospective, case-control study was to detect the efficacy and safety of carboxymethyl β-glucan (Colpofix®) gel as adjuvant therapy in HPV infection.
METHODS: The medical records of patients attending the Colposcopy Service of four hospitals in Rome from 2011 to 2013 were collected. Case arm consisted of patients submitted to local therapy with Colpofix®. Control arm comprised patients who did not receive this therapy. A total of 999 patients were included, divided into four groups, according to their cytological and histological specimens, colposcopy and subsequent management.
RESULTS: Local therapy with Colpofix® gel resulted effective with respect to no therapy for the regression of low-grade CIN (CIN1) in patients submitted to follow up (P=0.0204), while it was no effective for the regression of CIN1 submitted to ablative therapy and high-grade CIN (CIN 2+) (P value not significant).
CONCLUSIONS: In conclusion, Colpofix® gel represents a valid alternative to “wait and see” strategy in patients affected by CIN1. Further prospective studies are warranted to confirm these results.


KEY WORDS: Papillomaviridae - Cervical intraepithelial neoplasia - Beta-glucans

top of page